Design and evaluation of cyclodextrin-based drug formulation.
about
Obstructing toxin pathways by targeted pore blockageNanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A ReviewSearch for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities.Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel.Difluorobenzocyclooctyne: synthesis, reactivity, and stabilization by beta-cyclodextrin.Renin-angiotensin system in the kidney: What is new?Preparation of naringenin/ β-cyclodextrin complex and its more potent alleviative effect on choroidal neovascularization in rats.Advanced technologies for oral controlled release: cyclodextrins for oral controlled release.Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats.Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategiesCyclodextrins in drug delivery.Naftifine: a review.Recent advances and future directions in amphiphilic cyclodextrin nanoparticles.Statins therapy: a review on conventional and novel formulation approaches.Advanced taste sensors based on artificial lipids with global selectivity to basic taste qualities and high correlation to sensory scores.New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis.Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review.Docetaxel nanotechnology in anticancer therapy.Molecular buckets: cyclodextrins for oral cancer therapy.Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.Cyclodextrin-based multivalent glycodisplays: covalent and supramolecular conjugates to assess carbohydrate-protein interactions.Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA.Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for DNA, shRNA and siRNA.Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling.Cyclodextrin and phospholipid complexation in solubility and dissolution enhancement: a critical and meta-analysis.Model predicting impact of complexation with cyclodextrins on oral absorption.Theory and practice of supersaturatable formulations for poorly soluble drugs.Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.Recent advances in cyclodextrin delivery techniques.Synthesis and anti-HCV entry activity studies of β-cyclodextrin-pentacyclic triterpene conjugates.Biocompatible Polymeric Analogues of DMSO Prepared by Atom Transfer Radical Polymerization.Cyclodextrins inhibit replication of scrapie prion protein in cell culture.Carbohydrate-Based Host-Guest Complexation of Hydrophobic Antibiotics for the Enhancement of Antibacterial Activity.An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect.Parenteral delivery of HPβCD: effects on drug-HSA binding.Improvement of dissolution behavior for poorly water-soluble drug by application of cyclodextrin in extrusion process: comparison between melt extrusion and wet extrusion.Sugar-Responsive Pseudopolyrotaxane Composed of Phenylboronic Acid-Modified Polyethylene Glycol and γ-CyclodextrinOral bioavailability of a poorly aqueous drug from three different SBE7-β-cyclodextrin based formulations in beagle dogs.A Cyclodextrin-Based Photoresponsive Molecular Gate that Functions Independently of Either Solvent or Potentially Competitive Guests.Fertility of cold-stored mouse sperm is recovered by promoting acrosome reaction and hyperactivation after cholesterol efflux by methyl-beta-cyclodextrin.
P2860
Q26827489-A18AE4D4-EC3A-43D8-B40A-39250F6BE283Q28394719-418759FB-4717-49BF-9B02-8CE992BE1862Q30445260-49E46221-8E4C-40D5-9B9D-4824621F7148Q33563610-1BF2A511-705D-44FE-9B02-329AC1FC15BBQ34072621-59D45841-B9C2-460D-9997-F75B95230728Q34367671-0E3958F0-A333-43FE-9FF1-A27917C31739Q35162838-F9EC82A7-3173-4121-8593-C731A728DFCEQ35577222-B0FFBA98-8D36-42B8-A10F-9717A319666CQ35609223-628CA9AB-D2F7-4051-81A9-A23CCE542F5BQ35940287-B57CBC4A-8677-4451-8894-A29B3665A3AFQ36316735-7B655D20-6CB3-4FBD-82D4-7958A03FEC23Q37112042-ED71C18B-DFD4-48D1-BE71-CFD184CF1432Q37586465-D99EC491-D030-400D-9485-7C45539B73FEQ37896125-58CA0C8E-C9E1-44CC-9DED-4C3B95BCB1D7Q37982697-8BB90B73-9EAE-45D6-B676-EA5B0A117F13Q37982718-F4EF3673-2D3E-4E52-94F9-B2BA5E119C1FQ38003191-EB46B879-1355-481B-AFF4-71145A79B42FQ38003964-3277FA21-5B8E-4DF2-883F-BFAE5CC70676Q38029632-EAB6AF4C-4BD9-4F0C-97B0-6C40B23E661CQ38065112-626E3DE4-484C-4064-BA43-EDDE3AF15050Q38076027-600CED70-A994-4446-9A6E-E73D44ED9844Q38167284-DF8AF490-530F-44ED-AFDA-15A5DC2D9439Q38168355-09687B42-CDDE-429F-A6D6-D9363B794754Q38193206-052D9FDF-2752-442F-83B3-76569C6EA40FQ38218602-9B3D54FC-25F0-4AE4-A9B3-7196F41B7E25Q38316288-B2F02BC4-6ECC-4858-BD27-6A16BCD73CD5Q38411345-9C1DAD19-7A5F-47C2-9D81-DCE92CF721FAQ38470559-7AF250AE-B5BE-4BAC-90D0-272436524CB5Q38534300-44B6D27F-2346-4018-82D1-27A71CA220B0Q39016028-618FDA66-562B-4997-9C4B-FDDE99C0FAE9Q39038639-F4226E1A-9945-4F11-AE4B-9EF1F1A75C98Q40093984-2BB3B94C-17E8-4B86-BA85-637F98A59176Q40102211-0A21CC07-ECAD-4973-BAE0-00DAB02751E0Q41830683-F7E344A6-06DA-4943-8872-E3919E5C2AD3Q41898234-CB5D1BA0-2FE7-418D-AD86-473DC02781F5Q41988850-349C219D-A409-45BC-88AE-9E02371587FAQ42228244-CAA456D5-B190-4185-BC42-19705626E8D0Q42854119-17DF11B4-91F1-4012-BF74-8A6528F115A0Q48140570-A88B1E4A-1BE1-410E-B5B8-2DFC6B73DB7EQ50890646-80293C90-06F1-43D8-9B8A-CA84150A1B1B
P2860
Design and evaluation of cyclodextrin-based drug formulation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Design and evaluation of cyclodextrin-based drug formulation.
@ast
Design and evaluation of cyclodextrin-based drug formulation.
@en
type
label
Design and evaluation of cyclodextrin-based drug formulation.
@ast
Design and evaluation of cyclodextrin-based drug formulation.
@en
prefLabel
Design and evaluation of cyclodextrin-based drug formulation.
@ast
Design and evaluation of cyclodextrin-based drug formulation.
@en
P356
P1476
Design and evaluation of cyclodextrin-based drug formulation.
@en
P2093
Kaneto Uekama
P304
P356
10.1248/CPB.52.900
P407
P577
2004-08-01T00:00:00Z